Abstract
One hundred and thirty-one patients (118 evaluable) with disseminated breast cancer were treated with a combination of 5-fluorouracil + Oncovin + Adriamycin + mitomycin C (FOAM). The objective response rate for 82 evaluable patients whose disease was refractory to previous CMF or L-PAM chemotherapy was 35%; that for 36 evaluable patients who had not previously received chemotherapy, 56%. The hematologic toxicity of this therapy was generally mild and acceptable. It is believed that FOAM is an effective therapy for patients whose tumors are resistant to CMF.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols*
-
Breast Neoplasms / drug therapy*
-
Clinical Trials as Topic
-
Doxorubicin / administration & dosage
-
Drug Therapy, Combination
-
Female
-
Fluorouracil / administration & dosage
-
Humans
-
Leukocyte Count
-
Middle Aged
-
Mitomycin
-
Mitomycins / administration & dosage
-
Platelet Count
-
Prognosis
-
Vincristine / administration & dosage
Substances
-
Antineoplastic Agents
-
Mitomycins
-
Mitomycin
-
Vincristine
-
Doxorubicin
-
Fluorouracil